BioXcel Therapeutics Inc.

BTAI | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.18

-$0.54 (-74.96%)

Aug 28, 2026, 4:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $22.19M

Enterprise Value $97.21M

Beta 0.29

Average Volume 908.95K

Shares Outstanding (Diluted) 30.3M

Shares Change YoY 286.33%

Institutional Ownership 44.57%

Exchange NASDAQ

ISIN US09075P2048

Price Performance

Price Change 1M -78.4%

Price Change 3M -84.8%

Price Change 6M -88.9%

Price Change YTD -89.3%

Price Change 1Y -95.6%

Price Change 3Y -99.7%

Price Change 5Y -100.0%

1M CAGR (ann.) -17.4%

1Y CAGR (ann.) -86.3%

5Y CAGR (ann.) -71.6%

All-Time CAGR -47.8%

Valuation

PE Ratio -0.04

Forward PE N/A

PEG Ratio -0.00

Forward PEG N/A

PS Ratio 7.55

Forward PS 0.30

PB Ratio -0.05

P/FCF Ratio -0.11

P/Adj. FCF Ratio -0.11

P/OCF Ratio -0.04

EV/Sales 131.01

EV/EBIT -2.25

EV/EBITDA -1.83

EV/FCF -1.91

Earnings Yield -2633.3%

FCF Yield -908.8%

Adj. FCF Yield -941.4%

Financial Health

Net Debt $91.61M

Total Debt $104.45M

Cash & Short-Term Investments $12.84M

Total Assets $28.8M

Current Ratio 0.21

Quick Ratio 0.21

Debt / Equity Ratio -0.90

Debt / EBITDA -1.96

Debt / FCF -2.05

OCF / Debt -0.49

Interest Coverage -2.59

Altman Z-Score -45.69

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 45.3%

Operating Profit Margin -6014.4%

EBITDA Margin -7198.3%

Net Profit Margin -9549.9%

FCF Margin -6860.4%

Adj. FCF Margin -7106.2%

SBC / Revenue 245.8%

SBC Impact (per share) -3.6%

Returns

Return on Assets -246.1%

Return on Equity 69.9%

Return on Invested Capital 1144.6%

Return on Capital Employed 41.2%

Return on Tangible Assets -246.1%

Historical Growth (CAGR)

Revenue CAGR 3Y 19.6%

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y 31.3%

EPS CAGR 5Y 18.1%

EPS CAGR 10Y -79.5%

FCF CAGR 3Y 19.2%

FCF CAGR 5Y 2.7%

FCF CAGR 10Y -2040.4%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 15

EPS Growth Next 3Y 29.0%

Revenue Growth Next 3Y 522.3%

Earnings Date Nov 10, 2026

EPS Estimate (next Q) -$1.01

EPS Growth Est (next Q) -53.7%

Revenue Est (next Q) $191.39K

Revenue Growth Est (next Q) 95.3%

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $12

Price Target Upside 6566.7%

Cash Flow

Operating Cash Flow $-50.9M

Free Cash Flow $-50.9M

Adj. Free Cash Flow $-52.73M

FCF Per Share -$4.17

OCF Per Share -$4.17

OCF/S Ratio -6860.4%

Income Statement

Revenue $742K

Gross Profit $176K

Operating Income $-44.63M

EBITDA $-53.17M

Net Income $-70.86M

EPS (Diluted) -$4.74

Revenue / Employee $25.59K

Profit / Employee $-2.44M

Employees 29